=====================
Our New Pick is: KNHBF
Current Price: $0.25
Investor Presentation
========================
Members,
Earlier this week, we told you that we were looking for the perfect trade idea that could deliver easy profits during this brutal bear market.
After scanning the market for quite some time, we've decided not to take any chances, and just go with a company that has proven itself to be a winner each and every time we've alerted it to our members.
Please turn your immediate to attention back to our #1 cannabis play of 2018 KNHBF (ICC International Cannabis Corp.)
We plan on ending this 2019 on a high-note with this past +100% winner!
We first brought KNHBF to your attention back on September 27 when it was flying under the radar at just $0.44 per share.
In less than two week's time, shares of KNHBF rallied as high as $0.90, representing multi-day gains of up to +104.55% for our members.
We are just as excited about KNHBF now as we were back in late September.
In fact, the upside is even more attractive now.
Shares of KNHBF traded down to $0.25 yesterday, creating the perfect buying opportunity for those looking to cash in on the cannabis boom at a ground floor price.
We've been keeping a close eye on this red-hot cannabis play, and we believe that right now could be the perfect entry point for those looking for a piece of this cannabis company committed to growth
Here's why...
On Oct. 17, Canada becomes the second and largest country with a legal national marijuana marketplace.
KNHBF has been issued the FIRST EVER medical cannabis cultivation license by the Greek government.
Broke ground on Colombian Centre of Excellence for Cannabis Propagation; Marking Initialization of 10-Hectare Cannabis Park
Announced the creation of the world’s first fully electronic cannabis marketplace through a partnership with GreenTree International, the parent company of Amercanex, which operates a secure Electronic Cannabis Market (ECM) called ACExchange.
Completed 100% Acquisition of Enigma Unipessoal LDA - a company who controls one of the first hemp licenses issued in Portugal
Entered into a definitive agreement to acquire 100 percent of Balkan Cannabis Corp (“Balkan Cannabis”). Balkan Cannabis controls Macedonian medical Cannabis cultivation and extraction licenses, as well as Bulgarian medical Cannabis and hemp cultivation licenses.
Increased their European distribution footprint by over 1,300 pharmacies
As you can see KNHBF is deeply committed to strengthening its grip on the European cannabis market.
With a population twice the size of the US and Canada combined, and a cannabis market still in its relative infancy, Europe presents an enormous opportunity.
KNHBF has been dropping big news almost daily, and we would not be surprised if the Company announced another major milestone today.
This could be one of your last chances to start a position in KNHBF for a under $1 per share....
That being said, we are urging all members to start their research on this past +100% winner immediately, and be ready to take action this morning at 9:30AM EST!
About ICC International Cannabis Corp.
Via its diversified portfolio of companies and subsidiaries, ICC International Cannabis intends to further establish itself as a international Cannabis industry consolidation platform. The Company’s mission is to inspire holistic wellness by augmenting the design, development and production of the world’s most innovative and best performing Cannabis products and facilities.
Through its subsidiaries, KNHBF has agreements in place for European-based pharmaceutical distribution, wholesale importation, research and development, as well as working interests in industrial hemp licenses in Greece, licenses to cultivate, produce, distribute, store, and export Cannabis and Cannabis derivatives in Colombia, the Kingdom of Lesotho, Africa and Denmark.
Company Highlights:
110 clients representing approximately 36,300 pharmacies in 16 countries
13 hectacres of optimal agricultural land dedicated to cannabis cultivation located in Funza, Colombia
16 acres of fertile agricultural land dedicated to industrial cultivation and CBD extractuib siturated within the Greek prefecture of Imathia
2,400 pharmacies included in their distribution portfolio of independent and corporate pharmacies across South Africa
55k sq/ft fully automated IMC-GAP, ISO:9001 and European GMP compliant greenhouse facility to be constructed in Denmark
9 licenses or cultivation, spanning three continents
KNHBF's Current Holdings
Marathon Global Inc.
Marathon Global has an exclusive agreement with Cosmos Holdings, a European based pharmaceutical distributor, to procure and distribute medical cannabis products and all cannabis derivatives for clients of Cosmos in approved countries within its distribution network of 110 clients, representing approximately 35,000 pharmacies in 16 countries. Marathon Global brings an unparalleled ability to supply the overwhelming demand for cannabis and cannabis extracts in Europe as Cosmos brings generations worth of experience and relationship to Kaneh Bosm. This distribution strategy carries on the Company’s existing distribution business through its unique BioCanna ADM retail system.
EU Cannabis Corp.
EU Cannabis has an option to acquire a 90-per-cent working interest in industrial hemp licenses held by Cannatec Greece A.E. Cannatech currently holds three licenses covering a total of 16 acres situated within the Greek prefecture of Imathia. These licenses were granted to Cannatec by the Hellenic Republic Ministry of Agricultural Development and Food, and permit EU Cannabis to cultivate, manufacture, distribute and export industrial hemp and its many cannabidiol (CBD) derived extracts. Greece boasts over 300 days of unadulterated sunshine per year, resulting in attractive climate for outdoor industrial hemp cultivation. The alignment of the company’s existing distribution channels, revolutionary
ADM retail system along with EU Cannabis’s robust extraction capabilities will assist in appeasing an expanding appetite for functional CBD products within the European Union.
Danavian Cannabis Ltd.
Danavian controls licenses for cannabis cultivation and manufacturing in the Kingdom of Denmark. Kaneh Bosm’s entry into Denmark mirrors industry peers such as Canopy Growth Corporation, Green Organic Dutchman Holdings, Aurora Cannabis Inc. and CannTrust Holdings.
Danavian has engaged an Israeli cannabis organic cultivation and management company, Sababa Sciences Inc. (“Sababa Sciences”). Sababa Sciences will provide end-to-end management including the implementation of advanced Israeli agricultural technologies for high quality medical cannabis treatments. Danavian and Sababa Sciences have designed a 55,000 square foot, fully automated greenhouse facility that will meet IMC-GAP, ISO:9001 and European GMP standards. Finished cannabis and cannabis derivatives produced by Danavian will be sold through Denmark’s retail pharmacy network.
Danavian holds claim to premier European cannabis assets; domiciled in a jurisdiction with a highly skilled agriculture and manufacturing workforce. Davavian also boasts various industry relationships that will complement future development potential throughout Scandinavia. Continued development of Danavian’s Danish cannabis portfolio will help serve both local and export market demand. Danavian is tactically positioned in immediate proximity to Germany, allowing for direct imports of CBD products, as well as medical cannabis flower.
CanAfrica Holdings
CanAfrica holds a license to cultivate, manufacture, supply, hold, import, export and transport cannabis and derivative products. The Kingdom of Lesotho, Africa, has an ideal climate for low-cost greenhouse cannabis production. It averages over 300 days of sunshine annually. Lesotho was the first African nation to legalize medical cannabis in 2017.
The Company believes that by establishing a presence in Africa, it will extend its current business model and allow the company to produce its own products to push through its unique and substantial European distribution networks and into its award-winning BioCanna ADM automated retail system.
Aricannabis
Aricannabis works on an exclusive basis with NuCare Health (“NuCare”) to provide Cannabis products to over 2,800 independent and corporate pharmacies across South Africa. NuCare also provides their medical partners with the following:
Access to innovative consumer products;
Strategic partnerships with key suppliers;
Management of channel pressure; and
Educational and training resources.
The alignment of the Kaneh Bosm’s existing African cultivation capabilities and distribution channels, complemented by these new established marketing and distribution channels will augment the Company’s African seed-to-sale objectives.
Cannabis Medical Group SAS
Cannabis Medical Group SAS, a Colombian entity that holds licenses to cultivate, produce, hold, sell and export cannabis and cannabis derivatives.
Colombia has become a highly sought-after jurisdiction for cannabis cultivation activities as it has a world-leading combination of broad public and private sector acceptance, ideal growing conditions, and a massive addressable market.
Cannabis Medical Group previously acquired 13 hectares of optimal agricultural land located in Funza, the heart of the Bogota savanna, which is also one of the safest areas in Colombia. It is conveniently located within a 20-kilometre drive to Bogota’s international airport. The lease on this land has been prepaid for a period of 10 years.
BioCanna ADM Retail System
The BioCanna ADM retail system is an intelligent automated retail kiosk for the dispensing of Cannabis and related products in both medical and commercial markets.
The BioCanna ADM retail system offers a solution to many of the concerns related to controlling access to ensure that only properly identified and qualified clients can obtain marijuana products. With strict regulations in place throughout the North American Cannabis market the BioCanna ADM could offer Cannabis retailers a means to meet and surpass regulated requirements. The BioCanna ADM retail system is unique in this sector as it encompasses the 5 crucial elements identified by Ret. Major Neill Franklin, executive director of LEAP for safe, reliable and successful automated Cannabis retail. Those elements are:
Access control (no minors or un-prescribed patients)
Purchase volume control (monthly or daily quantity limits)
Secure storage of product (climate controlled and theft proof)
Transactional oversight by regulators via software monitoring
Proven track record in a controlled substance/products environment
The proprietary software system, which operates the BioCanna ADM, offers regulatory bodies the ability to dynamically observe transactions in real-time at every Kiosk located within their legal jurisdiction.
As you can see KNHBF is well positioned to monetize the cannabis sector from every possible angle!
You would be hard pressed to find a company better positioned for growth in this multi billion dollar market than KNHBF.
Recent Developments:
International Cannabis Increases European Distribution Footprint by Over 1,300 Pharmacies
Last week, the Company announced that its exclusive European distribution partner, Cosmos Holdings, Inc. (“Cosmos”), has acquired Greek pharmaceutical wholesaler, Cosmofarm Ltd. (“Cosmofarm”).
Established in 1994, Athens based Cosmofarm provides a comprehensive range of pharmaceutical products to over 1,130 pharmacies. Cosmofarm has been authorized and endorsed by Greece’s National Organization for Medicines under Good Distribution Practices to distribute over-the-counter pharmaceuticals, natural and health food supplements, as well as branded and generic medicines.
Cosmofarm is equipped with an extensive supplier network of approximately 250 pharmaceutical manufacturers and realized sales of nearly US$14 million for the fiscal year 2017. Cosmofarm is in the process of relocating its operations to a new 32,000 square foot facility, increasing its manufacturing capacities by 2,000%. The facility’s state-of-the-art manufacturing operations include a robotic fulfillment center and will significantly improve Cosmofarm’s scaling and distribution capabilities.
Eugene Beukman, chief executive officer and a director of International Cannabis, stated: “International Cannabis applauds the acquisition of Cosmofarm, which further augments the Company’s robust European distribution capabilities. Cosmofarm is a rapidly growing wholesaler with embedded shared-values of innovation and high-quality distribution. This transaction is once again demonstrative of International Cannabis’ mandate of creating sustainable shareholder value, through the strategic acquisition of revenue generating assets. The Company will leverage Cosmofarm’s distribution channels and robotic fulfillment centre to facilitate its growing pipeline of purchase orders in 2019”.
International Cannabis will market and sell its cannabis and cannabidiol (“CBD”) products throughout the 28 eligible member states of the European Union (“EU”). The EU has over 500 million potential consumers, affording International Cannabis a unique opportunity to service this high-growth marketplace.
Furthermore, the Company plans further leverage Cosmofarm’s 32,000 square foot facility to manufacture and distribute white-labeled CBD products from its Greek industrial hemp cultivation operations. International Cannabis controls three hemp licenses spanning a total of 16 acres situated within the Greek prefecture of Imathia. These licenses permit the Company cultivate, manufacture, distribute and export industrial hemp and its many CBD derived extracts. Greece boasts over 300 days of unadulterated sunshine per year, resulting in attractive climate for outdoor industrial hemp cultivation.
International Cannabis will leverage Cosmos Holdings Inc.'s robust distribution network, representing approximately 36,130 pharmacies to market and sell its cannabis and CBD products. The Company, through its wholly owned subsidiary Marathon Global Inc., has an exclusive agreement with Cosmos, a European-based pharmaceutical distributor.
Cosmos has a trans-European network of over 160 clients and vendors, which expands to 16 countries, including: Germany, United Kingdom, Ireland, United Arab Emirates, Denmark, Italy, France, Singapore, Spain, Lebanon, Skopje, Jordan, Sweden, Poland, the Netherlands and Greece. This European distribution network is augmented by various value-added services, including strategic procurement, warehousing, product registrations and regulatory representations.
International Cannabis, through its subsidiaries, has agreements in place for European-based pharmaceutical distribution, wholesale importation, and research and development, as well as licenses to cultivate, produce, distribute, store and export cannabis, cannabis derivatives and industrial hemp in Colombia, Denmark, Poland, Greece, Portugal, Poland, Macedonia, Bulgaria, South Africa and the Kingdom of Lesotho.
Market Outlook
Marijuana: A $75 Billion Market by 2030?
This investment bank just increased its sales forecast for the cannabis industry by 50%.
It's also a market that's expected to see continued robust sales growth. ArcView pegged North American legal-weed growth at 33% last year, to $9.7 billion, and it's forecasted $47 billion in annual sales in a decade's time. Yet even this aggressive estimate may undercut the true potential of the cannabis industry.
The hemp-derived CBD market is forecast to be especially lucrative, and a 2017 report by Brightfield Group – a cannabis & CBD market research organization – predicted a per annum increase of 55% over the next five years alone.
The Marijuana Industry Could be Much Bigger Than You Realize
According to a new note published this past week by investment firm Cowen, the total cannabis market could generate as much as $75 billion in gross annual sales by 2030, up from a previous forecast of $50 billion by 2026.
The investment bank's initial forecast was released in September 2016 via a 110-page report from beverage, tobacco, and cannabis sector analyst Vivien Azer and her team. The report, "The Cannabis Compendium: Cross-Sector Views on a Budding Industry," highlighted the many potential applications of legal cannabis and outlined pathways that would allow the weed industry to reach $50 billion in sales by 2026. Chief to that thesis is the expected legalization of marijuana in the U.S. at some point before 2026.
The investment bank's new note lifts its projected sales estimate by another 50% ($25 billion), while adding on just four additional years. Cowen offered six reasons behind its decision to become even more bullish on the outlook for marijuana. Chief among them was proprietary data on binge-drinking statistics among U.S. states that showed a notable decline in binge drinking below the national average in states that had legalized cannabis. It's Cowen's assumption that as more states legalize pot, binge-drinking rates would be expected to fall as consumers opt for cannabis in place of alcohol.
Additionally, Cowen finds that the cannabis market is already worth about $50 billion, albeit with black-market channels being accounted for. If you factor in per-capita spending of $1,500 a year, 50% higher than it previously forecast, along with 35 million annual cannabis users, you can see where the bulk of this $25 billion annual increase from its 2016 projections is coming from.
Cowen even suggests that the United States' fight against the opioid epidemic could lead to an increase in cannabis consumption. Per the report, "Newly published research reinforces the work that we have already done, showing that for some, cannabis is an effective opioid substitute (in particular in treating chronic pain)."
Technical Analysis
KNHBF has never looked more attractive.
Yesterday's ten percent drop in price just created the ultimate "buy the dip" opportunity for our members.
KNHBF's RSI is hovering just above oversold levels, and we believe that a major bullish reversal is in the making.
We also know how fast this stock can move from first hand experience.
When we last brought it to your attention, shares of KNHBF made intraday swings as high as +57.39%!
A run back to its 52-week of $0.90 would show our members up to +260% in pure profit!
Don't miss out on KNHBF's next potential +100% rally!
This is our last trade idea of 2018! And we plan on ending the year on a high note.
As such, we are urging all members to act fast, start their research on KNHBF, and be ready to take action at 9:30AM EST!
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The PennyStock101 Team
Don't Miss Our Next Huge Winner...
Text 'PS101' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated ten thousand dollars by ICC International Cannabis Corp. to conduct investor relations advertising and marketing for KNHBF. We have been previously compensated ten thousand dollars by ICC International Cannabis Corp. to conduct investor relations advertising and marketing for KNHBF-which has expired. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
Our New Pick is: KNHBF
Current Price: $0.25
Investor Presentation
========================
Members,
Earlier this week, we told you that we were looking for the perfect trade idea that could deliver easy profits during this brutal bear market.
After scanning the market for quite some time, we've decided not to take any chances, and just go with a company that has proven itself to be a winner each and every time we've alerted it to our members.
Please turn your immediate to attention back to our #1 cannabis play of 2018 KNHBF (ICC International Cannabis Corp.)
We plan on ending this 2019 on a high-note with this past +100% winner!
We first brought KNHBF to your attention back on September 27 when it was flying under the radar at just $0.44 per share.
In less than two week's time, shares of KNHBF rallied as high as $0.90, representing multi-day gains of up to +104.55% for our members.
We are just as excited about KNHBF now as we were back in late September.
In fact, the upside is even more attractive now.
Shares of KNHBF traded down to $0.25 yesterday, creating the perfect buying opportunity for those looking to cash in on the cannabis boom at a ground floor price.
We've been keeping a close eye on this red-hot cannabis play, and we believe that right now could be the perfect entry point for those looking for a piece of this cannabis company committed to growth
Here's why...
On Oct. 17, Canada becomes the second and largest country with a legal national marijuana marketplace.
KNHBF has been issued the FIRST EVER medical cannabis cultivation license by the Greek government.
Broke ground on Colombian Centre of Excellence for Cannabis Propagation; Marking Initialization of 10-Hectare Cannabis Park
Announced the creation of the world’s first fully electronic cannabis marketplace through a partnership with GreenTree International, the parent company of Amercanex, which operates a secure Electronic Cannabis Market (ECM) called ACExchange.
Completed 100% Acquisition of Enigma Unipessoal LDA - a company who controls one of the first hemp licenses issued in Portugal
Entered into a definitive agreement to acquire 100 percent of Balkan Cannabis Corp (“Balkan Cannabis”). Balkan Cannabis controls Macedonian medical Cannabis cultivation and extraction licenses, as well as Bulgarian medical Cannabis and hemp cultivation licenses.
Increased their European distribution footprint by over 1,300 pharmacies
As you can see KNHBF is deeply committed to strengthening its grip on the European cannabis market.
With a population twice the size of the US and Canada combined, and a cannabis market still in its relative infancy, Europe presents an enormous opportunity.
KNHBF has been dropping big news almost daily, and we would not be surprised if the Company announced another major milestone today.
This could be one of your last chances to start a position in KNHBF for a under $1 per share....
That being said, we are urging all members to start their research on this past +100% winner immediately, and be ready to take action this morning at 9:30AM EST!
About ICC International Cannabis Corp.
Via its diversified portfolio of companies and subsidiaries, ICC International Cannabis intends to further establish itself as a international Cannabis industry consolidation platform. The Company’s mission is to inspire holistic wellness by augmenting the design, development and production of the world’s most innovative and best performing Cannabis products and facilities.
Through its subsidiaries, KNHBF has agreements in place for European-based pharmaceutical distribution, wholesale importation, research and development, as well as working interests in industrial hemp licenses in Greece, licenses to cultivate, produce, distribute, store, and export Cannabis and Cannabis derivatives in Colombia, the Kingdom of Lesotho, Africa and Denmark.
Company Highlights:
110 clients representing approximately 36,300 pharmacies in 16 countries
13 hectacres of optimal agricultural land dedicated to cannabis cultivation located in Funza, Colombia
16 acres of fertile agricultural land dedicated to industrial cultivation and CBD extractuib siturated within the Greek prefecture of Imathia
2,400 pharmacies included in their distribution portfolio of independent and corporate pharmacies across South Africa
55k sq/ft fully automated IMC-GAP, ISO:9001 and European GMP compliant greenhouse facility to be constructed in Denmark
9 licenses or cultivation, spanning three continents
KNHBF's Current Holdings
Marathon Global Inc.
Marathon Global has an exclusive agreement with Cosmos Holdings, a European based pharmaceutical distributor, to procure and distribute medical cannabis products and all cannabis derivatives for clients of Cosmos in approved countries within its distribution network of 110 clients, representing approximately 35,000 pharmacies in 16 countries. Marathon Global brings an unparalleled ability to supply the overwhelming demand for cannabis and cannabis extracts in Europe as Cosmos brings generations worth of experience and relationship to Kaneh Bosm. This distribution strategy carries on the Company’s existing distribution business through its unique BioCanna ADM retail system.
EU Cannabis Corp.
EU Cannabis has an option to acquire a 90-per-cent working interest in industrial hemp licenses held by Cannatec Greece A.E. Cannatech currently holds three licenses covering a total of 16 acres situated within the Greek prefecture of Imathia. These licenses were granted to Cannatec by the Hellenic Republic Ministry of Agricultural Development and Food, and permit EU Cannabis to cultivate, manufacture, distribute and export industrial hemp and its many cannabidiol (CBD) derived extracts. Greece boasts over 300 days of unadulterated sunshine per year, resulting in attractive climate for outdoor industrial hemp cultivation. The alignment of the company’s existing distribution channels, revolutionary
ADM retail system along with EU Cannabis’s robust extraction capabilities will assist in appeasing an expanding appetite for functional CBD products within the European Union.
Danavian Cannabis Ltd.
Danavian controls licenses for cannabis cultivation and manufacturing in the Kingdom of Denmark. Kaneh Bosm’s entry into Denmark mirrors industry peers such as Canopy Growth Corporation, Green Organic Dutchman Holdings, Aurora Cannabis Inc. and CannTrust Holdings.
Danavian has engaged an Israeli cannabis organic cultivation and management company, Sababa Sciences Inc. (“Sababa Sciences”). Sababa Sciences will provide end-to-end management including the implementation of advanced Israeli agricultural technologies for high quality medical cannabis treatments. Danavian and Sababa Sciences have designed a 55,000 square foot, fully automated greenhouse facility that will meet IMC-GAP, ISO:9001 and European GMP standards. Finished cannabis and cannabis derivatives produced by Danavian will be sold through Denmark’s retail pharmacy network.
Danavian holds claim to premier European cannabis assets; domiciled in a jurisdiction with a highly skilled agriculture and manufacturing workforce. Davavian also boasts various industry relationships that will complement future development potential throughout Scandinavia. Continued development of Danavian’s Danish cannabis portfolio will help serve both local and export market demand. Danavian is tactically positioned in immediate proximity to Germany, allowing for direct imports of CBD products, as well as medical cannabis flower.
CanAfrica Holdings
CanAfrica holds a license to cultivate, manufacture, supply, hold, import, export and transport cannabis and derivative products. The Kingdom of Lesotho, Africa, has an ideal climate for low-cost greenhouse cannabis production. It averages over 300 days of sunshine annually. Lesotho was the first African nation to legalize medical cannabis in 2017.
The Company believes that by establishing a presence in Africa, it will extend its current business model and allow the company to produce its own products to push through its unique and substantial European distribution networks and into its award-winning BioCanna ADM automated retail system.
Aricannabis
Aricannabis works on an exclusive basis with NuCare Health (“NuCare”) to provide Cannabis products to over 2,800 independent and corporate pharmacies across South Africa. NuCare also provides their medical partners with the following:
Access to innovative consumer products;
Strategic partnerships with key suppliers;
Management of channel pressure; and
Educational and training resources.
The alignment of the Kaneh Bosm’s existing African cultivation capabilities and distribution channels, complemented by these new established marketing and distribution channels will augment the Company’s African seed-to-sale objectives.
Cannabis Medical Group SAS
Cannabis Medical Group SAS, a Colombian entity that holds licenses to cultivate, produce, hold, sell and export cannabis and cannabis derivatives.
Colombia has become a highly sought-after jurisdiction for cannabis cultivation activities as it has a world-leading combination of broad public and private sector acceptance, ideal growing conditions, and a massive addressable market.
Cannabis Medical Group previously acquired 13 hectares of optimal agricultural land located in Funza, the heart of the Bogota savanna, which is also one of the safest areas in Colombia. It is conveniently located within a 20-kilometre drive to Bogota’s international airport. The lease on this land has been prepaid for a period of 10 years.
BioCanna ADM Retail System
The BioCanna ADM retail system is an intelligent automated retail kiosk for the dispensing of Cannabis and related products in both medical and commercial markets.
The BioCanna ADM retail system offers a solution to many of the concerns related to controlling access to ensure that only properly identified and qualified clients can obtain marijuana products. With strict regulations in place throughout the North American Cannabis market the BioCanna ADM could offer Cannabis retailers a means to meet and surpass regulated requirements. The BioCanna ADM retail system is unique in this sector as it encompasses the 5 crucial elements identified by Ret. Major Neill Franklin, executive director of LEAP for safe, reliable and successful automated Cannabis retail. Those elements are:
Access control (no minors or un-prescribed patients)
Purchase volume control (monthly or daily quantity limits)
Secure storage of product (climate controlled and theft proof)
Transactional oversight by regulators via software monitoring
Proven track record in a controlled substance/products environment
The proprietary software system, which operates the BioCanna ADM, offers regulatory bodies the ability to dynamically observe transactions in real-time at every Kiosk located within their legal jurisdiction.
As you can see KNHBF is well positioned to monetize the cannabis sector from every possible angle!
You would be hard pressed to find a company better positioned for growth in this multi billion dollar market than KNHBF.
Recent Developments:
International Cannabis Increases European Distribution Footprint by Over 1,300 Pharmacies
Last week, the Company announced that its exclusive European distribution partner, Cosmos Holdings, Inc. (“Cosmos”), has acquired Greek pharmaceutical wholesaler, Cosmofarm Ltd. (“Cosmofarm”).
Established in 1994, Athens based Cosmofarm provides a comprehensive range of pharmaceutical products to over 1,130 pharmacies. Cosmofarm has been authorized and endorsed by Greece’s National Organization for Medicines under Good Distribution Practices to distribute over-the-counter pharmaceuticals, natural and health food supplements, as well as branded and generic medicines.
Cosmofarm is equipped with an extensive supplier network of approximately 250 pharmaceutical manufacturers and realized sales of nearly US$14 million for the fiscal year 2017. Cosmofarm is in the process of relocating its operations to a new 32,000 square foot facility, increasing its manufacturing capacities by 2,000%. The facility’s state-of-the-art manufacturing operations include a robotic fulfillment center and will significantly improve Cosmofarm’s scaling and distribution capabilities.
Eugene Beukman, chief executive officer and a director of International Cannabis, stated: “International Cannabis applauds the acquisition of Cosmofarm, which further augments the Company’s robust European distribution capabilities. Cosmofarm is a rapidly growing wholesaler with embedded shared-values of innovation and high-quality distribution. This transaction is once again demonstrative of International Cannabis’ mandate of creating sustainable shareholder value, through the strategic acquisition of revenue generating assets. The Company will leverage Cosmofarm’s distribution channels and robotic fulfillment centre to facilitate its growing pipeline of purchase orders in 2019”.
International Cannabis will market and sell its cannabis and cannabidiol (“CBD”) products throughout the 28 eligible member states of the European Union (“EU”). The EU has over 500 million potential consumers, affording International Cannabis a unique opportunity to service this high-growth marketplace.
Furthermore, the Company plans further leverage Cosmofarm’s 32,000 square foot facility to manufacture and distribute white-labeled CBD products from its Greek industrial hemp cultivation operations. International Cannabis controls three hemp licenses spanning a total of 16 acres situated within the Greek prefecture of Imathia. These licenses permit the Company cultivate, manufacture, distribute and export industrial hemp and its many CBD derived extracts. Greece boasts over 300 days of unadulterated sunshine per year, resulting in attractive climate for outdoor industrial hemp cultivation.
International Cannabis will leverage Cosmos Holdings Inc.'s robust distribution network, representing approximately 36,130 pharmacies to market and sell its cannabis and CBD products. The Company, through its wholly owned subsidiary Marathon Global Inc., has an exclusive agreement with Cosmos, a European-based pharmaceutical distributor.
Cosmos has a trans-European network of over 160 clients and vendors, which expands to 16 countries, including: Germany, United Kingdom, Ireland, United Arab Emirates, Denmark, Italy, France, Singapore, Spain, Lebanon, Skopje, Jordan, Sweden, Poland, the Netherlands and Greece. This European distribution network is augmented by various value-added services, including strategic procurement, warehousing, product registrations and regulatory representations.
International Cannabis, through its subsidiaries, has agreements in place for European-based pharmaceutical distribution, wholesale importation, and research and development, as well as licenses to cultivate, produce, distribute, store and export cannabis, cannabis derivatives and industrial hemp in Colombia, Denmark, Poland, Greece, Portugal, Poland, Macedonia, Bulgaria, South Africa and the Kingdom of Lesotho.
Market Outlook
Marijuana: A $75 Billion Market by 2030?
This investment bank just increased its sales forecast for the cannabis industry by 50%.
It's also a market that's expected to see continued robust sales growth. ArcView pegged North American legal-weed growth at 33% last year, to $9.7 billion, and it's forecasted $47 billion in annual sales in a decade's time. Yet even this aggressive estimate may undercut the true potential of the cannabis industry.
The hemp-derived CBD market is forecast to be especially lucrative, and a 2017 report by Brightfield Group – a cannabis & CBD market research organization – predicted a per annum increase of 55% over the next five years alone.
The Marijuana Industry Could be Much Bigger Than You Realize
According to a new note published this past week by investment firm Cowen, the total cannabis market could generate as much as $75 billion in gross annual sales by 2030, up from a previous forecast of $50 billion by 2026.
The investment bank's initial forecast was released in September 2016 via a 110-page report from beverage, tobacco, and cannabis sector analyst Vivien Azer and her team. The report, "The Cannabis Compendium: Cross-Sector Views on a Budding Industry," highlighted the many potential applications of legal cannabis and outlined pathways that would allow the weed industry to reach $50 billion in sales by 2026. Chief to that thesis is the expected legalization of marijuana in the U.S. at some point before 2026.
The investment bank's new note lifts its projected sales estimate by another 50% ($25 billion), while adding on just four additional years. Cowen offered six reasons behind its decision to become even more bullish on the outlook for marijuana. Chief among them was proprietary data on binge-drinking statistics among U.S. states that showed a notable decline in binge drinking below the national average in states that had legalized cannabis. It's Cowen's assumption that as more states legalize pot, binge-drinking rates would be expected to fall as consumers opt for cannabis in place of alcohol.
Additionally, Cowen finds that the cannabis market is already worth about $50 billion, albeit with black-market channels being accounted for. If you factor in per-capita spending of $1,500 a year, 50% higher than it previously forecast, along with 35 million annual cannabis users, you can see where the bulk of this $25 billion annual increase from its 2016 projections is coming from.
Cowen even suggests that the United States' fight against the opioid epidemic could lead to an increase in cannabis consumption. Per the report, "Newly published research reinforces the work that we have already done, showing that for some, cannabis is an effective opioid substitute (in particular in treating chronic pain)."
Technical Analysis
KNHBF has never looked more attractive.
Yesterday's ten percent drop in price just created the ultimate "buy the dip" opportunity for our members.
KNHBF's RSI is hovering just above oversold levels, and we believe that a major bullish reversal is in the making.
We also know how fast this stock can move from first hand experience.
When we last brought it to your attention, shares of KNHBF made intraday swings as high as +57.39%!
A run back to its 52-week of $0.90 would show our members up to +260% in pure profit!
Don't miss out on KNHBF's next potential +100% rally!
This is our last trade idea of 2018! And we plan on ending the year on a high note.
As such, we are urging all members to act fast, start their research on KNHBF, and be ready to take action at 9:30AM EST!
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The PennyStock101 Team
Don't Miss Our Next Huge Winner...
Text 'PS101' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated ten thousand dollars by ICC International Cannabis Corp. to conduct investor relations advertising and marketing for KNHBF. We have been previously compensated ten thousand dollars by ICC International Cannabis Corp. to conduct investor relations advertising and marketing for KNHBF-which has expired. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
Comment:
Buy the support (GREEN box) and Sell the resistance (RED box).
Comment:
Likely possibilities for KNHBF.
Likely possibilities for KNHBF.
Comment:
Members,
Just as expected, our #1 cannabis play of 2018 KNHBF (ICC International Cannabis Corp.) bounced back hard from yesterday's ten percent decline.
Shares of KNHBF hit a high of $0.273 this morning, representing a gain over +9.20% from our $0.25 alert price.
We believe that this morning's run-up is just a small taste of things to come from this rapidly growing cannabis company.
KNHBF has been dropping big news almost daily, and we would not be surprised if the Company announced another major milestone within the next few days.
Based on today's upward momentum, we feel pretty confident in saying that this could be the start of highly profitable bullish reversal.
Don't forget...
We first brought KNHBF to your attention back on September 27 when it was flying under the radar at just $0.44 per share.
In less than two week's time, shares of KNHBF rallied as high as $0.90, representing multi-day gains of up to +104.55% for our members.
We are just as excited about KNHBF now as we were back in late September.
In fact, the upside is even more attractive now.
We've been keeping a close eye on this red-hot cannabis play, and we believe that right now could be the perfect entry point for those looking for a piece of this cannabis company committed to growth
Here's why...
On Oct. 17, Canada becomes the second and largest country with a legal national marijuana marketplace.
KNHBF has been issued the FIRST EVER medical cannabis cultivation license by the Greek government.
Broke ground on Colombian Centre of Excellence for Cannabis Propagation; Marking Initialization of 10-Hectare Cannabis Park
Announced the creation of the world’s first fully electronic cannabis marketplace through a partnership with GreenTree International, the parent company of Amercanex, which operates a secure Electronic Cannabis Market (ECM) called ACExchange.
Completed 100% Acquisition of Enigma Unipessoal LDA - a company who controls one of the first hemp licenses issued in Portugal
Entered into a definitive agreement to acquire 100 percent of Balkan Cannabis Corp (“Balkan Cannabis”). Balkan Cannabis controls Macedonian medical Cannabis cultivation and extraction licenses, as well as Bulgarian medical Cannabis and hemp cultivation licenses.
Increased their European distribution footprint by over 1,300 pharmacies
As you can see KNHBF is deeply committed to strengthening its grip on the European cannabis market.
With a population twice the size of the US and Canada combined, and a cannabis market still in its relative infancy, Europe presents an enormous opportunity.
KNHBF's RSI is hovering just above oversold levels, and we believe that a major bullish reversal is in the making.
We also know how fast this stock can move from first hand experience.
When we last brought it to your attention, shares of KNHBF made intraday swings as high as +57.39%!
A run back to its 52-week of $0.90 would show our members up to +260% in pure profit!
Don't miss out on KNHBF's next potential +100% rally!
This could be one of your last chances to start a position in KNHBF for a under $1 per share....
As such, we are urging all members to act fast, and consider building a position in KNHBF today!
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The PennyStock101 Team
Just as expected, our #1 cannabis play of 2018 KNHBF (ICC International Cannabis Corp.) bounced back hard from yesterday's ten percent decline.
Shares of KNHBF hit a high of $0.273 this morning, representing a gain over +9.20% from our $0.25 alert price.
We believe that this morning's run-up is just a small taste of things to come from this rapidly growing cannabis company.
KNHBF has been dropping big news almost daily, and we would not be surprised if the Company announced another major milestone within the next few days.
Based on today's upward momentum, we feel pretty confident in saying that this could be the start of highly profitable bullish reversal.
Don't forget...
We first brought KNHBF to your attention back on September 27 when it was flying under the radar at just $0.44 per share.
In less than two week's time, shares of KNHBF rallied as high as $0.90, representing multi-day gains of up to +104.55% for our members.
We are just as excited about KNHBF now as we were back in late September.
In fact, the upside is even more attractive now.
We've been keeping a close eye on this red-hot cannabis play, and we believe that right now could be the perfect entry point for those looking for a piece of this cannabis company committed to growth
Here's why...
On Oct. 17, Canada becomes the second and largest country with a legal national marijuana marketplace.
KNHBF has been issued the FIRST EVER medical cannabis cultivation license by the Greek government.
Broke ground on Colombian Centre of Excellence for Cannabis Propagation; Marking Initialization of 10-Hectare Cannabis Park
Announced the creation of the world’s first fully electronic cannabis marketplace through a partnership with GreenTree International, the parent company of Amercanex, which operates a secure Electronic Cannabis Market (ECM) called ACExchange.
Completed 100% Acquisition of Enigma Unipessoal LDA - a company who controls one of the first hemp licenses issued in Portugal
Entered into a definitive agreement to acquire 100 percent of Balkan Cannabis Corp (“Balkan Cannabis”). Balkan Cannabis controls Macedonian medical Cannabis cultivation and extraction licenses, as well as Bulgarian medical Cannabis and hemp cultivation licenses.
Increased their European distribution footprint by over 1,300 pharmacies
As you can see KNHBF is deeply committed to strengthening its grip on the European cannabis market.
With a population twice the size of the US and Canada combined, and a cannabis market still in its relative infancy, Europe presents an enormous opportunity.
KNHBF's RSI is hovering just above oversold levels, and we believe that a major bullish reversal is in the making.
We also know how fast this stock can move from first hand experience.
When we last brought it to your attention, shares of KNHBF made intraday swings as high as +57.39%!
A run back to its 52-week of $0.90 would show our members up to +260% in pure profit!
Don't miss out on KNHBF's next potential +100% rally!
This could be one of your last chances to start a position in KNHBF for a under $1 per share....
As such, we are urging all members to act fast, and consider building a position in KNHBF today!
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The PennyStock101 Team